← All trials
NCT05733767
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 3, 2022
- Primary completion
- Jul 31, 2026
- Completion date
- Dec 31, 2027
- First posted
- Feb 17, 2023
- Last posted
- Dec 18, 2023
- Enrollment
- 424
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of MassachusettsLead sponsor
- University of MassachusettsOverall official - principal investigator
- Boston UniversityCollaborator
- University of Texas, AustinCollaborator
- University of MassachusettsOfficial
- University of MassachusettsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.